Frontoparietal cerebrovascular pathology is linked to oxygenation during REM sleep, indicating possible connection to Alzheimer Disease.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep apnoea pill.

Home sleep apnea tests (HSATs) use sophisticated sensors and algorithms to monitor your breathing patterns, oxygen levels, ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

AD109 met the primary endpoint, mean change in apnea-hypopnea index (AHI, p=0.001) at 26 weeks, across a broad range of people with mild, moderate and severe obstructive sleep apnea Study ...

Dotted lines indicate ranges of the 95% confidence interval ... The number of CVHR detected by the ACAT closely correlated (r=0.84) with the apnea-hypopnea index. The CVHR ≥15 episodes per hour ...

The standard measure of severity is the apnea-hypopnea index (AHI), which counts pauses ... And blood pressure, though not in the hypertensive range for anyone in the study, dropped in those ...

Statistics show that obstructive sleep apnea (OSA) is a common disorder affecting around 30 million adults in the US. In a recent press release, the American Food and Drug Administration has ...